NCT00984945 - Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

July 31, 2010

Conditions

Virus DiseasesRNA Virus InfectionsRespiratory Tract DiseasesRespiratory Tract Infections

Interventions

BIOLOGICAL

H5 VLP pandemic influenza vaccine 5 µg

0.5 mL, IM, 2 injections 21 days apart

BIOLOGICAL

H5 VLP pandemic influenza vaccine 10 µg

0.5 mL, IM, 2 injections 21 days apart

BIOLOGICAL

H5 VLP pandemic influenza vaccine 20 µg

0.5 mL, IM, two injections 21 days apart

BIOLOGICAL

Placebo

0.5 mL, IM, two injections 21 days apart

Trial Locations (1)

MUHC Vaccine Study Centre, Pierrefonds